Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Partial GABAc agonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Johnston (1996) GABAc receptors: relatively simple transmitter-gated ion channels? TiPS 17 319 PMID: 8885697
Kusama et al (1993) Pharmacology of GABA r1 and GABA α/β receptors expressed in Xenopus oocytes and COS cells. Br.J.Pharmacol. 109 200 PMID: 8388298
Keywords: Imidazole-4-acetic acid hydrochloride, Imidazole-4-acetic acid hydrochloride supplier, I4AA, GABAA-rho, Receptors, 0815, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Imidazole-4-acetic acid hydrochloride.
There are currently no reviews for this product. Be the first to review Imidazole-4-acetic acid hydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Ian Martin, Norman Bowery and Susan Dunn, this review provides a history of the GABA receptor, as well as discussing the structure and function of the various subtypes and the clinical potential of receptor modulators; compounds available from Tocris are listed.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.